KR20200139236A - 헤테로탠덤 비사이클릭 펩티드 복합체 - Google Patents

헤테로탠덤 비사이클릭 펩티드 복합체 Download PDF

Info

Publication number
KR20200139236A
KR20200139236A KR1020207031802A KR20207031802A KR20200139236A KR 20200139236 A KR20200139236 A KR 20200139236A KR 1020207031802 A KR1020207031802 A KR 1020207031802A KR 20207031802 A KR20207031802 A KR 20207031802A KR 20200139236 A KR20200139236 A KR 20200139236A
Authority
KR
South Korea
Prior art keywords
μmol
compound
seq
bicyclic peptide
hereinafter referred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207031802A
Other languages
English (en)
Korean (ko)
Inventor
니콜라스 킨
케빈 맥도넬
피터 박
푸닛 우파디야야
젬마 머드
Original Assignee
바이사이클티엑스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1805492.4A external-priority patent/GB201805492D0/en
Priority claimed from GBGB1820981.7A external-priority patent/GB201820981D0/en
Application filed by 바이사이클티엑스 리미티드 filed Critical 바이사이클티엑스 리미티드
Publication of KR20200139236A publication Critical patent/KR20200139236A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020207031802A 2018-04-04 2019-04-02 헤테로탠덤 비사이클릭 펩티드 복합체 Ceased KR20200139236A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1805492.4 2018-04-04
GBGB1805492.4A GB201805492D0 (en) 2018-04-04 2018-04-04 Heterotandem Bicyclic peptide complexes
GB1820981.7 2018-12-21
GBGB1820981.7A GB201820981D0 (en) 2018-12-21 2018-12-21 Heterotandem bicyclic peptide complexes
PCT/GB2019/050951 WO2019193328A1 (en) 2018-04-04 2019-04-02 Heterotandem bicyclic peptide complexes

Publications (1)

Publication Number Publication Date
KR20200139236A true KR20200139236A (ko) 2020-12-11

Family

ID=66175434

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207031802A Ceased KR20200139236A (ko) 2018-04-04 2019-04-02 헤테로탠덤 비사이클릭 펩티드 복합체

Country Status (12)

Country Link
US (2) US11453703B2 (enExample)
EP (1) EP3774851A1 (enExample)
JP (2) JP7551500B2 (enExample)
KR (1) KR20200139236A (enExample)
CN (1) CN112236442A (enExample)
AU (2) AU2019247795B2 (enExample)
BR (1) BR112020020349A2 (enExample)
CA (1) CA3095582A1 (enExample)
IL (1) IL277717A (enExample)
MX (1) MX2020010444A (enExample)
SG (1) SG11202009773VA (enExample)
WO (1) WO2019193328A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
KR20200139236A (ko) * 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128526A1 (en) * 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
CN113260420A (zh) * 2018-12-21 2021-08-13 拜斯科阿迪有限公司 Pd-l1特异性的双环肽配体
CN113811541A (zh) 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP2022544246A (ja) * 2019-08-13 2022-10-17 バイスクルテクス・リミテッド 修飾された多量体二環式ペプチドリガンド
PL4464721T3 (pl) * 2019-10-03 2025-08-25 Bicycletx Limited Heterotandemowe kompleksy peptydów bicyklicznych
GB201914872D0 (en) * 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
GB202016331D0 (en) * 2020-10-15 2020-12-02 Bicyclerd Ltd Bicyclic peptide ligand drug conjugates
US20240197897A1 (en) * 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) * 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022253051A1 (zh) * 2021-06-01 2022-12-08 南京明德新药研发有限公司 多肽偶联药物及其应用
US20250121076A1 (en) * 2021-08-17 2025-04-17 Medshine Discovery Inc. Polypeptide drug conjugate having novel structure and application thereof
TWI803993B (zh) * 2021-09-28 2023-06-01 廖嘉鴻 環胜肽自組裝3d微粒裝置及其製造方法
AU2022356942B2 (en) * 2021-09-29 2025-07-03 Conjustar (Zhuhai) Biologics Co., Ltd. Tricyclic polypeptide conjugated drug and use thereof
CN115819618B (zh) * 2022-09-16 2023-10-27 哈尔滨工业大学 一种光激活的纳抗偶联物二聚化诱导剂pancid及其应用
WO2025248261A1 (en) 2024-05-31 2025-12-04 Bicycletx Limited Method for identifying patients

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
US8680022B2 (en) 2008-02-05 2014-03-25 Bicycle Therapeutics Limited Methods and compositions
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
CA2777242A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
PL2764140T3 (pl) * 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
US20140274759A1 (en) * 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR102426765B1 (ko) * 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Cd137에 대한 신규한 이중특이성 폴리펩타이드
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
KR20200139236A (ko) * 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) * 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
JP2022528887A (ja) 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
PL4464721T3 (pl) 2019-10-03 2025-08-25 Bicycletx Limited Heterotandemowe kompleksy peptydów bicyklicznych
IL293200A (en) 2019-11-27 2022-07-01 Bicycletx Ltd Bicyclic peptide ligands specific for epha2 and uses thereof

Also Published As

Publication number Publication date
JP2021520378A (ja) 2021-08-19
US20190307836A1 (en) 2019-10-10
US11453703B2 (en) 2022-09-27
SG11202009773VA (en) 2020-10-29
EP3774851A1 (en) 2021-02-17
IL277717A (en) 2020-11-30
CA3095582A1 (en) 2019-10-10
US20230008076A1 (en) 2023-01-12
CN112236442A (zh) 2021-01-15
AU2019247795B2 (en) 2024-08-15
AU2024205105A1 (en) 2024-10-10
JP2024062998A (ja) 2024-05-10
MX2020010444A (es) 2021-01-08
JP7551500B2 (ja) 2024-09-17
AU2019247795A1 (en) 2020-11-12
US20210299210A2 (en) 2021-09-30
BR112020020349A2 (pt) 2021-01-05
WO2019193328A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
US20230008076A1 (en) Heterotandem bicyclic peptide complexes
JP7704732B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP7770607B2 (ja) ヘテロタンデム二環式ペプチド複合体
JP2023081907A (ja) Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2024261490A1 (en) Bicyclic peptide ligands specific for nk cells
HK40123165A (en) Heterotandem bicyclic peptide complexes
EA045834B1 (ru) Гетеротандемные бициклические пептидные комплексы

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000